Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic Carcinoma

Abroad (travel likely)RecruitingPHASE2

Conditions

Thymic Carcinoma · Thymoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
Contact: Study coordinator (Wen Gao) · Yoghurt831030@126.com · +8613951619963

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma

B2 Thymoma · Thymic Carcinoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Shenzhen, China

HEARTS Trial for Thoracic Cancers

Non-Small Cell Lung Cancer (Stage III) · Esophageal Cancer Stage I-III · Esophagogastric Cancer Stage I-III

Abroad (travel likely)RecruitingPHASE2

Madison, United States

A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors

Thymoma · Thymic Carcinoma

Abroad (travel likely)RecruitingPHASE2

Palo Alto, United States · Washington D.C., United States

Clinical Study of Carbon Ion Radiotherapy Combined With Chemotherapy for Thymic Epithelial Tumors

Carbon Ion Radiotherapy, Thymoma, Thymic Carcinoma, Radiotherapy, Chemotherapy

Abroad (travel likely)RecruitingPHASE2

Shanghai, China